BTIG Maintains Buy on Macrogenics, Raises Price Target to $24
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman has maintained a Buy rating on Macrogenics (NASDAQ:MGNX) and doubled the price target from $12 to $24, indicating a positive outlook on the company's future performance.
March 04, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Kaveri Pohlman has reaffirmed a Buy rating on Macrogenics and increased the price target to $24, signaling strong confidence in the company's prospects.
The doubling of the price target by a reputable analyst suggests a strong bullish sentiment towards Macrogenics. This significant increase is likely based on positive developments within the company or its market potential, which could lead to increased investor interest and a potential rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100